Compass Pathways PLC Sponsored ADR $CMPS Stock: Candriam S.C.A. Grows Holdings

Candriam S.C.A. lifted its position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 18.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,510,695 shares of the company’s stock after buying an additional 236,417 shares during the period. Candriam S.C.A.’s holdings in Compass Pathways were worth $18,862,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Alps Advisors Inc. boosted its holdings in Compass Pathways by 34.4% in the third quarter. Alps Advisors Inc. now owns 183,458 shares of the company’s stock valued at $2,282,000 after acquiring an additional 46,996 shares during the last quarter. CenterBook Partners LP increased its stake in Compass Pathways by 454.1% during the third quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock worth $8,658,000 after acquiring an additional 570,349 shares during the last quarter. Pekin Hardy Strauss Inc. acquired a new stake in Compass Pathways during the third quarter worth about $792,000. Commonwealth Equity Services LLC increased its stake in Compass Pathways by 81.0% during the third quarter. Commonwealth Equity Services LLC now owns 23,482 shares of the company’s stock worth $292,000 after acquiring an additional 10,510 shares during the last quarter. Finally, Integrity Alliance LLC. purchased a new position in shares of Compass Pathways in the 3rd quarter worth about $128,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Price Performance

Shares of NASDAQ CMPS opened at $8.61 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50. Compass Pathways PLC Sponsored ADR has a 1-year low of $4.88 and a 1-year high of $15.87. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43. The business has a 50-day moving average of $12.32 and a 200-day moving average of $10.41.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.08. On average, equities analysts anticipate that Compass Pathways PLC Sponsored ADR will post -0.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CMPS has been the topic of several research analyst reports. B. Riley Financial lifted their price objective on Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Thursday, October 15th. HC Wainwright dropped their target price on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Morgan Stanley raised their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.